| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Histiocytosis, Langerhans-Cell | 68 | 2025 | 231 | 13.020 |
Why?
|
| Lymphohistiocytosis, Hemophagocytic | 25 | 2021 | 159 | 5.870 |
Why?
|
| Proto-Oncogene Proteins B-raf | 18 | 2025 | 220 | 2.940 |
Why?
|
| Histiocytosis, Sinus | 11 | 2026 | 35 | 2.620 |
Why?
|
| Erdheim-Chester Disease | 9 | 2025 | 28 | 2.410 |
Why?
|
| Xanthogranuloma, Juvenile | 6 | 2022 | 32 | 1.790 |
Why?
|
| Autoimmune Lymphoproliferative Syndrome | 3 | 2020 | 6 | 1.170 |
Why?
|
| Mutation | 19 | 2024 | 6197 | 1.140 |
Why?
|
| Macrophage Activation Syndrome | 3 | 2018 | 10 | 1.110 |
Why?
|
| Neurodegenerative Diseases | 5 | 2025 | 290 | 1.050 |
Why?
|
| Epstein-Barr Virus Infections | 5 | 2020 | 295 | 0.970 |
Why?
|
| Histiocytosis | 3 | 2020 | 18 | 0.850 |
Why?
|
| Humans | 128 | 2026 | 132041 | 0.810 |
Why?
|
| Cytarabine | 6 | 2023 | 102 | 0.770 |
Why?
|
| Infant | 41 | 2025 | 13343 | 0.760 |
Why?
|
| Ferritins | 5 | 2018 | 111 | 0.740 |
Why?
|
| Child, Preschool | 43 | 2025 | 15089 | 0.700 |
Why?
|
| Tumor Necrosis Factor-alpha | 3 | 2018 | 644 | 0.700 |
Why?
|
| Langerhans Cells | 4 | 2021 | 21 | 0.680 |
Why?
|
| Central Nervous System Diseases | 3 | 2010 | 99 | 0.660 |
Why?
|
| Child | 57 | 2026 | 26361 | 0.660 |
Why?
|
| Pneumothorax | 1 | 2020 | 81 | 0.600 |
Why?
|
| Rituximab | 2 | 2018 | 175 | 0.590 |
Why?
|
| Etanercept | 1 | 2018 | 44 | 0.580 |
Why?
|
| Lung Diseases | 2 | 2020 | 403 | 0.570 |
Why?
|
| Biological Products | 1 | 2020 | 143 | 0.560 |
Why?
|
| Thalidomide | 3 | 2026 | 39 | 0.550 |
Why?
|
| Osteopontin | 1 | 2018 | 52 | 0.550 |
Why?
|
| Male | 63 | 2025 | 65425 | 0.530 |
Why?
|
| Interleukin-18 | 1 | 2018 | 78 | 0.530 |
Why?
|
| Hodgkin Disease | 6 | 2026 | 312 | 0.530 |
Why?
|
| Vinblastine | 6 | 2014 | 55 | 0.530 |
Why?
|
| MAP Kinase Signaling System | 6 | 2024 | 305 | 0.530 |
Why?
|
| Adolescent | 36 | 2025 | 21018 | 0.520 |
Why?
|
| Herpesvirus 4, Human | 9 | 2021 | 647 | 0.510 |
Why?
|
| Mannose-Binding Lectins | 6 | 2020 | 26 | 0.500 |
Why?
|
| Female | 62 | 2025 | 71380 | 0.500 |
Why?
|
| Protein Kinase Inhibitors | 5 | 2024 | 621 | 0.500 |
Why?
|
| Lectins, C-Type | 6 | 2020 | 69 | 0.490 |
Why?
|
| Dendritic Cells | 10 | 2020 | 437 | 0.480 |
Why?
|
| Lymphocytes | 2 | 2015 | 358 | 0.480 |
Why?
|
| Adult | 30 | 2025 | 31747 | 0.470 |
Why?
|
| Leukocytes, Mononuclear | 3 | 2025 | 359 | 0.470 |
Why?
|
| Hydroxyurea | 1 | 2016 | 88 | 0.470 |
Why?
|
| Diagnosis, Differential | 10 | 2025 | 1916 | 0.460 |
Why?
|
| Lymphoproliferative Disorders | 4 | 2021 | 218 | 0.460 |
Why?
|
| Immunosuppressive Agents | 4 | 2017 | 666 | 0.460 |
Why?
|
| Antigens, CD | 6 | 2020 | 418 | 0.460 |
Why?
|
| Skin Neoplasms | 1 | 2023 | 905 | 0.450 |
Why?
|
| Antineoplastic Agents | 4 | 2020 | 1811 | 0.440 |
Why?
|
| fas Receptor | 2 | 2014 | 43 | 0.440 |
Why?
|
| Positron-Emission Tomography | 4 | 2013 | 296 | 0.440 |
Why?
|
| Pore Forming Cytotoxic Proteins | 1 | 2014 | 19 | 0.440 |
Why?
|
| Lysosomal-Associated Membrane Protein 1 | 1 | 2014 | 15 | 0.440 |
Why?
|
| Fluorodeoxyglucose F18 | 4 | 2019 | 128 | 0.430 |
Why?
|
| Nervous System Diseases | 1 | 2018 | 400 | 0.430 |
Why?
|
| Cell Degranulation | 1 | 2014 | 28 | 0.430 |
Why?
|
| Epistasis, Genetic | 1 | 2014 | 98 | 0.420 |
Why?
|
| Bone Diseases | 2 | 2012 | 44 | 0.410 |
Why?
|
| Remission Induction | 6 | 2023 | 308 | 0.410 |
Why?
|
| Histiocytosis, Non-Langerhans-Cell | 4 | 2003 | 16 | 0.380 |
Why?
|
| Mercaptopurine | 4 | 2013 | 72 | 0.380 |
Why?
|
| Vincristine | 3 | 2010 | 194 | 0.370 |
Why?
|
| Interleukin-17 | 2 | 2011 | 129 | 0.360 |
Why?
|
| Cellular Senescence | 2 | 2026 | 216 | 0.360 |
Why?
|
| Disease Management | 5 | 2020 | 561 | 0.350 |
Why?
|
| Cell Differentiation | 6 | 2026 | 1950 | 0.350 |
Why?
|
| Bone and Bones | 3 | 2014 | 300 | 0.350 |
Why?
|
| Magnetic Resonance Imaging | 11 | 2023 | 3931 | 0.350 |
Why?
|
| Models, Genetic | 1 | 2014 | 752 | 0.350 |
Why?
|
| Methotrexate | 3 | 2013 | 344 | 0.340 |
Why?
|
| Prednisone | 6 | 2014 | 245 | 0.340 |
Why?
|
| Immune System Diseases | 1 | 2011 | 52 | 0.340 |
Why?
|
| Dexamethasone | 2 | 2026 | 260 | 0.330 |
Why?
|
| Autoimmune Diseases | 3 | 2020 | 268 | 0.320 |
Why?
|
| Cyclosporine | 2 | 2017 | 131 | 0.320 |
Why?
|
| Antibodies, Monoclonal, Humanized | 4 | 2023 | 573 | 0.320 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 6 | 2023 | 1270 | 0.310 |
Why?
|
| Epidermis | 1 | 2010 | 64 | 0.310 |
Why?
|
| Brain Neoplasms | 2 | 2022 | 1306 | 0.310 |
Why?
|
| Bone Marrow | 5 | 2020 | 313 | 0.300 |
Why?
|
| Skin Diseases | 5 | 2015 | 142 | 0.300 |
Why?
|
| Predictive Value of Tests | 3 | 2014 | 2315 | 0.290 |
Why?
|
| Hematologic Neoplasms | 3 | 2017 | 314 | 0.290 |
Why?
|
| Infant, Newborn | 9 | 2020 | 8613 | 0.280 |
Why?
|
| Clinical Trials as Topic | 5 | 2020 | 1140 | 0.270 |
Why?
|
| Myeloid Cells | 4 | 2023 | 114 | 0.270 |
Why?
|
| Histiocytes | 2 | 2018 | 18 | 0.270 |
Why?
|
| Adenine Nucleotides | 3 | 2024 | 37 | 0.270 |
Why?
|
| Arabinonucleosides | 3 | 2024 | 34 | 0.270 |
Why?
|
| Immunotherapy | 2 | 2018 | 760 | 0.260 |
Why?
|
| Hydrocephalus | 1 | 2010 | 292 | 0.260 |
Why?
|
| Sepsis | 3 | 2021 | 500 | 0.250 |
Why?
|
| Hematopoietic Stem Cells | 4 | 2021 | 550 | 0.250 |
Why?
|
| Reed-Sternberg Cells | 1 | 2026 | 19 | 0.240 |
Why?
|
| Granuloma, Plasma Cell | 1 | 2005 | 4 | 0.240 |
Why?
|
| Brain Diseases | 2 | 2005 | 305 | 0.240 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2008 | 169 | 0.230 |
Why?
|
| Antimetabolites | 1 | 2005 | 28 | 0.230 |
Why?
|
| Gene Expression Profiling | 2 | 2026 | 1849 | 0.230 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 3 | 2014 | 157 | 0.230 |
Why?
|
| Prognosis | 10 | 2020 | 4962 | 0.230 |
Why?
|
| Recurrence | 7 | 2024 | 1484 | 0.230 |
Why?
|
| Endocrine System Diseases | 1 | 2025 | 43 | 0.220 |
Why?
|
| Salvage Therapy | 3 | 2024 | 177 | 0.220 |
Why?
|
| Inflammation | 3 | 2021 | 1503 | 0.220 |
Why?
|
| HLA-DR4 Antigen | 1 | 2003 | 6 | 0.210 |
Why?
|
| Castleman Disease | 1 | 2004 | 14 | 0.210 |
Why?
|
| Biomarkers | 5 | 2020 | 3422 | 0.210 |
Why?
|
| HLA-C Antigens | 1 | 2003 | 11 | 0.210 |
Why?
|
| Biopsy | 4 | 2018 | 1254 | 0.200 |
Why?
|
| Lymph Nodes | 4 | 2020 | 364 | 0.200 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2005 | 304 | 0.200 |
Why?
|
| Drug Therapy, Combination | 6 | 2014 | 1173 | 0.190 |
Why?
|
| Retrospective Studies | 14 | 2022 | 17748 | 0.190 |
Why?
|
| Immunocompromised Host | 2 | 2019 | 313 | 0.190 |
Why?
|
| Disease-Free Survival | 3 | 2016 | 910 | 0.180 |
Why?
|
| Middle Aged | 10 | 2025 | 28946 | 0.180 |
Why?
|
| Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2022 | 66 | 0.180 |
Why?
|
| Parvoviridae Infections | 2 | 2009 | 34 | 0.180 |
Why?
|
| Promoter Regions, Genetic | 2 | 2007 | 1220 | 0.170 |
Why?
|
| Central Nervous System | 1 | 2003 | 286 | 0.170 |
Why?
|
| Phenotype | 4 | 2019 | 4540 | 0.170 |
Why?
|
| Germ-Line Mutation | 3 | 2022 | 375 | 0.170 |
Why?
|
| Positron Emission Tomography Computed Tomography | 2 | 2019 | 81 | 0.160 |
Why?
|
| Polymorphism, Genetic | 1 | 2003 | 793 | 0.160 |
Why?
|
| Pleurodesis | 1 | 2020 | 15 | 0.160 |
Why?
|
| Chest Tubes | 1 | 2020 | 38 | 0.160 |
Why?
|
| Liver Diseases | 2 | 2018 | 385 | 0.160 |
Why?
|
| Molecular Biology | 1 | 2020 | 68 | 0.160 |
Why?
|
| Cladribine | 3 | 2022 | 9 | 0.160 |
Why?
|
| Chemoradiotherapy | 2 | 2018 | 120 | 0.160 |
Why?
|
| Treatment Outcome | 12 | 2024 | 13025 | 0.160 |
Why?
|
| Child Abuse | 1 | 2003 | 223 | 0.160 |
Why?
|
| Diabetes Insipidus | 4 | 2010 | 16 | 0.160 |
Why?
|
| Young Adult | 7 | 2025 | 10128 | 0.160 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 5 | 2024 | 1352 | 0.150 |
Why?
|
| Consensus | 3 | 2022 | 529 | 0.150 |
Why?
|
| Macrophage Activation | 1 | 2019 | 64 | 0.150 |
Why?
|
| Drug Eruptions | 1 | 2019 | 34 | 0.150 |
Why?
|
| Practice Guidelines as Topic | 5 | 2018 | 1306 | 0.150 |
Why?
|
| Lymphoma, T-Cell | 1 | 2019 | 64 | 0.140 |
Why?
|
| Skin | 2 | 2021 | 553 | 0.140 |
Why?
|
| Biliary Tract Diseases | 1 | 2018 | 33 | 0.140 |
Why?
|
| Liver Failure | 1 | 2019 | 99 | 0.140 |
Why?
|
| Tomography, X-Ray Computed | 4 | 2013 | 2130 | 0.140 |
Why?
|
| Disseminated Intravascular Coagulation | 1 | 2018 | 66 | 0.140 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2018 | 89 | 0.140 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2021 | 494 | 0.140 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2021 | 462 | 0.140 |
Why?
|
| Metabolism, Inborn Errors | 1 | 2019 | 125 | 0.140 |
Why?
|
| Brain | 3 | 2023 | 3251 | 0.140 |
Why?
|
| Smad6 Protein | 1 | 2017 | 8 | 0.130 |
Why?
|
| Age of Onset | 1 | 2019 | 631 | 0.130 |
Why?
|
| Etoposide | 1 | 2017 | 117 | 0.130 |
Why?
|
| Fatal Outcome | 3 | 2010 | 364 | 0.130 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2017 | 106 | 0.130 |
Why?
|
| Polymerase Chain Reaction | 4 | 2009 | 1490 | 0.130 |
Why?
|
| Cytokines | 3 | 2021 | 1356 | 0.130 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2018 | 3428 | 0.120 |
Why?
|
| Thiophenes | 1 | 2016 | 68 | 0.120 |
Why?
|
| Neoadjuvant Therapy | 1 | 2018 | 406 | 0.120 |
Why?
|
| Bone Marrow Cells | 1 | 2017 | 244 | 0.120 |
Why?
|
| Alemtuzumab | 4 | 2023 | 89 | 0.120 |
Why?
|
| Radiation Dosage | 2 | 2013 | 137 | 0.110 |
Why?
|
| Fetal Diseases | 1 | 2019 | 461 | 0.110 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2016 | 164 | 0.110 |
Why?
|
| Genetic Testing | 2 | 2021 | 1105 | 0.110 |
Why?
|
| Vaginal Diseases | 1 | 2015 | 18 | 0.110 |
Why?
|
| Thoracic Surgery, Video-Assisted | 1 | 2015 | 57 | 0.110 |
Why?
|
| Antigens | 1 | 2015 | 106 | 0.110 |
Why?
|
| Arthritis, Juvenile | 1 | 2015 | 45 | 0.110 |
Why?
|
| Perforin | 1 | 2014 | 26 | 0.110 |
Why?
|
| Survival Rate | 2 | 2017 | 2154 | 0.110 |
Why?
|
| Glycoproteins | 3 | 2020 | 348 | 0.110 |
Why?
|
| MAP Kinase Kinase 1 | 1 | 2014 | 45 | 0.110 |
Why?
|
| Philadelphia Chromosome | 1 | 2014 | 42 | 0.110 |
Why?
|
| Fusion Proteins, bcr-abl | 1 | 2014 | 44 | 0.110 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2016 | 244 | 0.110 |
Why?
|
| Risk Factors | 8 | 2018 | 11020 | 0.110 |
Why?
|
| Interleukin-2 Receptor alpha Subunit | 1 | 2014 | 53 | 0.110 |
Why?
|
| Immune System | 1 | 2015 | 98 | 0.100 |
Why?
|
| Cell Movement | 1 | 2017 | 882 | 0.100 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2016 | 482 | 0.100 |
Why?
|
| Parvovirus | 1 | 1993 | 7 | 0.100 |
Why?
|
| Pyrazoles | 1 | 2016 | 358 | 0.100 |
Why?
|
| Genome-Wide Association Study | 2 | 2018 | 1847 | 0.100 |
Why?
|
| Early Detection of Cancer | 1 | 2017 | 418 | 0.100 |
Why?
|
| Antibodies, Monoclonal | 3 | 2011 | 984 | 0.100 |
Why?
|
| Case-Control Studies | 6 | 2018 | 3457 | 0.090 |
Why?
|
| Registries | 2 | 2018 | 1601 | 0.090 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2018 | 934 | 0.090 |
Why?
|
| Antigens, CD1 | 3 | 2020 | 23 | 0.090 |
Why?
|
| Texas | 4 | 2018 | 3646 | 0.090 |
Why?
|
| STAT3 Transcription Factor | 1 | 2014 | 234 | 0.090 |
Why?
|
| Translocation, Genetic | 1 | 2014 | 350 | 0.090 |
Why?
|
| Burkitt Lymphoma | 1 | 2013 | 134 | 0.090 |
Why?
|
| Aged | 5 | 2024 | 21288 | 0.090 |
Why?
|
| Mice | 6 | 2021 | 18394 | 0.090 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2013 | 189 | 0.090 |
Why?
|
| Neutropenia | 1 | 1993 | 206 | 0.090 |
Why?
|
| Lymphoma, B-Cell | 1 | 2013 | 149 | 0.090 |
Why?
|
| Neoplasms | 3 | 2019 | 2968 | 0.090 |
Why?
|
| Apoptosis | 3 | 2026 | 1863 | 0.080 |
Why?
|
| Genome, Human | 1 | 2018 | 1338 | 0.080 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2011 | 792 | 0.080 |
Why?
|
| ROC Curve | 2 | 2014 | 624 | 0.080 |
Why?
|
| Parents | 1 | 2018 | 1121 | 0.080 |
Why?
|
| Genetic Diseases, Inborn | 1 | 2014 | 468 | 0.080 |
Why?
|
| Reproducibility of Results | 1 | 2017 | 3003 | 0.080 |
Why?
|
| Gene Expression Regulation, Viral | 1 | 1991 | 126 | 0.080 |
Why?
|
| T-Lymphocytes | 1 | 2019 | 1705 | 0.080 |
Why?
|
| Critical Illness | 1 | 2015 | 616 | 0.080 |
Why?
|
| Histiocytic Sarcoma | 1 | 2010 | 5 | 0.080 |
Why?
|
| CD3 Complex | 1 | 2010 | 93 | 0.080 |
Why?
|
| Parvovirus B19, Human | 1 | 2009 | 26 | 0.080 |
Why?
|
| Systemic Inflammatory Response Syndrome | 2 | 2021 | 209 | 0.080 |
Why?
|
| Animals | 7 | 2021 | 34262 | 0.070 |
Why?
|
| Mortality | 1 | 2011 | 261 | 0.070 |
Why?
|
| Blood Cells | 1 | 2019 | 55 | 0.070 |
Why?
|
| Genotype | 1 | 2015 | 2655 | 0.070 |
Why?
|
| Thalassemia | 1 | 2008 | 8 | 0.070 |
Why?
|
| Gene Amplification | 1 | 2009 | 227 | 0.070 |
Why?
|
| Biomarkers, Tumor | 2 | 2014 | 1621 | 0.070 |
Why?
|
| Iron Overload | 1 | 2008 | 18 | 0.070 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2013 | 1279 | 0.070 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2008 | 62 | 0.070 |
Why?
|
| Asparaginase | 1 | 2008 | 51 | 0.070 |
Why?
|
| Liver | 2 | 2019 | 1805 | 0.070 |
Why?
|
| Doxorubicin | 2 | 2008 | 301 | 0.070 |
Why?
|
| CD8 Antigens | 1 | 2007 | 39 | 0.070 |
Why?
|
| Cell Division | 1 | 2009 | 720 | 0.070 |
Why?
|
| Virus Activation | 1 | 2008 | 87 | 0.070 |
Why?
|
| Odds Ratio | 1 | 2011 | 1237 | 0.070 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2009 | 142 | 0.070 |
Why?
|
| DNA Primers | 2 | 2007 | 609 | 0.060 |
Why?
|
| Mycoses | 1 | 2008 | 113 | 0.060 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2010 | 1009 | 0.060 |
Why?
|
| Erythrocyte Transfusion | 1 | 2008 | 142 | 0.060 |
Why?
|
| Cell Survival | 1 | 2009 | 849 | 0.060 |
Why?
|
| Radiography | 1 | 2009 | 763 | 0.060 |
Why?
|
| Mice, Inbred C57BL | 3 | 2021 | 4733 | 0.060 |
Why?
|
| Databases, Genetic | 1 | 2019 | 504 | 0.060 |
Why?
|
| DNA Mutational Analysis | 2 | 2009 | 804 | 0.060 |
Why?
|
| Bacterial Infections | 1 | 2009 | 326 | 0.060 |
Why?
|
| Cell Proliferation | 2 | 2021 | 2477 | 0.060 |
Why?
|
| Lymphocyte Activation | 1 | 2007 | 633 | 0.060 |
Why?
|
| Pituitary Diseases | 1 | 2025 | 9 | 0.060 |
Why?
|
| Disease Progression | 3 | 2018 | 2229 | 0.060 |
Why?
|
| Roseolovirus Infections | 2 | 2003 | 30 | 0.060 |
Why?
|
| Hematopoietic Cell Growth Factors | 1 | 2005 | 9 | 0.060 |
Why?
|
| RNA, Messenger | 1 | 2011 | 2585 | 0.060 |
Why?
|
| Bone Marrow Transplantation | 2 | 2010 | 590 | 0.060 |
Why?
|
| Antibodies, Neoplasm | 1 | 2005 | 54 | 0.060 |
Why?
|
| Herpesvirus 6, Human | 2 | 2003 | 54 | 0.060 |
Why?
|
| Fever | 2 | 2009 | 312 | 0.060 |
Why?
|
| Pedigree | 2 | 2009 | 1719 | 0.050 |
Why?
|
| Secondary Prevention | 1 | 2005 | 220 | 0.050 |
Why?
|
| Anemia, Sickle Cell | 1 | 2008 | 325 | 0.050 |
Why?
|
| Treatment Failure | 1 | 2025 | 353 | 0.050 |
Why?
|
| Models, Biological | 1 | 2009 | 1394 | 0.050 |
Why?
|
| DNA, Viral | 3 | 2002 | 452 | 0.050 |
Why?
|
| Lymphocyte Subsets | 1 | 2003 | 38 | 0.050 |
Why?
|
| Chemokine CXCL9 | 1 | 2023 | 14 | 0.050 |
Why?
|
| Melphalan | 1 | 2023 | 44 | 0.050 |
Why?
|
| Multiple Organ Failure | 2 | 2018 | 144 | 0.050 |
Why?
|
| Lymphoma, AIDS-Related | 1 | 2003 | 27 | 0.050 |
Why?
|
| Cytomegalovirus Infections | 2 | 2003 | 225 | 0.050 |
Why?
|
| Sensitivity and Specificity | 1 | 2008 | 2148 | 0.050 |
Why?
|
| Cell Lineage | 2 | 2015 | 350 | 0.050 |
Why?
|
| MutS Homolog 2 Protein | 1 | 2022 | 39 | 0.050 |
Why?
|
| MutL Protein Homolog 1 | 1 | 2022 | 52 | 0.050 |
Why?
|
| DNA Mismatch Repair | 1 | 2022 | 45 | 0.050 |
Why?
|
| Remission, Spontaneous | 1 | 2002 | 65 | 0.050 |
Why?
|
| Mucocutaneous Lymph Node Syndrome | 1 | 2003 | 78 | 0.050 |
Why?
|
| Antigens, Neoplasm | 1 | 2005 | 402 | 0.050 |
Why?
|
| Genetic Markers | 2 | 2007 | 605 | 0.050 |
Why?
|
| Fatigue | 1 | 2023 | 199 | 0.050 |
Why?
|
| Neoplasm Staging | 2 | 2013 | 1333 | 0.050 |
Why?
|
| Head | 1 | 2022 | 115 | 0.040 |
Why?
|
| Neoplastic Syndromes, Hereditary | 1 | 2022 | 81 | 0.040 |
Why?
|
| Multicenter Studies as Topic | 1 | 2002 | 300 | 0.040 |
Why?
|
| CD11c Antigen | 2 | 2014 | 40 | 0.040 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2023 | 222 | 0.040 |
Why?
|
| Prospective Studies | 3 | 2020 | 6539 | 0.040 |
Why?
|
| Gene Expression Regulation | 1 | 2009 | 2357 | 0.040 |
Why?
|
| Drug Synergism | 1 | 2021 | 240 | 0.040 |
Why?
|
| Immunity | 1 | 2021 | 179 | 0.040 |
Why?
|
| Cytomegalovirus | 1 | 2002 | 259 | 0.040 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2005 | 1249 | 0.040 |
Why?
|
| Mice, Transgenic | 2 | 2021 | 2364 | 0.040 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2008 | 849 | 0.040 |
Why?
|
| Pain | 1 | 2023 | 439 | 0.040 |
Why?
|
| Autoimmunity | 1 | 2021 | 176 | 0.040 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2021 | 189 | 0.040 |
Why?
|
| HIV Infections | 2 | 2003 | 2040 | 0.040 |
Why?
|
| Follow-Up Studies | 3 | 2019 | 5287 | 0.040 |
Why?
|
| Cells, Cultured | 2 | 2017 | 2947 | 0.040 |
Why?
|
| Tissue Donors | 1 | 2023 | 504 | 0.040 |
Why?
|
| Sirolimus | 1 | 2021 | 230 | 0.040 |
Why?
|
| Immunoglobulins, Intravenous | 2 | 2015 | 147 | 0.040 |
Why?
|
| Proteome | 1 | 2021 | 288 | 0.040 |
Why?
|
| Oximes | 1 | 2019 | 55 | 0.040 |
Why?
|
| Interferon-gamma | 1 | 2021 | 542 | 0.040 |
Why?
|
| Neuroimaging | 1 | 2022 | 406 | 0.040 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2021 | 427 | 0.040 |
Why?
|
| Immunohistochemistry | 2 | 2017 | 1614 | 0.040 |
Why?
|
| Neomycin | 1 | 1998 | 36 | 0.040 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2026 | 2020 | 0.040 |
Why?
|
| Imidazoles | 1 | 2019 | 222 | 0.030 |
Why?
|
| Mutation, Missense | 2 | 2014 | 937 | 0.030 |
Why?
|
| Genetic Association Studies | 1 | 2021 | 837 | 0.030 |
Why?
|
| Molecular Targeted Therapy | 1 | 2020 | 387 | 0.030 |
Why?
|
| Adrenal Cortex Hormones | 2 | 2018 | 338 | 0.030 |
Why?
|
| Radiotherapy | 1 | 2018 | 120 | 0.030 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2020 | 610 | 0.030 |
Why?
|
| Lipopolysaccharide Receptors | 1 | 2017 | 53 | 0.030 |
Why?
|
| Foam Cells | 1 | 2017 | 21 | 0.030 |
Why?
|
| Drug Therapy | 1 | 2017 | 83 | 0.030 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2017 | 71 | 0.030 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2011 | 1236 | 0.030 |
Why?
|
| Multifactorial Inheritance | 1 | 2018 | 173 | 0.030 |
Why?
|
| Phagocytosis | 1 | 2017 | 191 | 0.030 |
Why?
|
| Cohort Studies | 2 | 2018 | 5124 | 0.030 |
Why?
|
| Immunophenotyping | 1 | 2017 | 337 | 0.030 |
Why?
|
| Mexico | 1 | 2016 | 198 | 0.030 |
Why?
|
| Cause of Death | 1 | 2018 | 511 | 0.030 |
Why?
|
| Colorectal Neoplasms | 1 | 2022 | 639 | 0.030 |
Why?
|
| Probability | 2 | 2008 | 310 | 0.030 |
Why?
|
| Stem Cell Transplantation | 1 | 2017 | 235 | 0.030 |
Why?
|
| Protein Domains | 1 | 2016 | 248 | 0.030 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 1998 | 512 | 0.030 |
Why?
|
| Enzyme Activation | 1 | 2016 | 589 | 0.030 |
Why?
|
| Receptors, Notch | 1 | 2017 | 204 | 0.030 |
Why?
|
| Monocytes | 1 | 2017 | 337 | 0.030 |
Why?
|
| Fever of Unknown Origin | 1 | 2015 | 44 | 0.030 |
Why?
|
| Drug Substitution | 1 | 2014 | 26 | 0.030 |
Why?
|
| United States | 3 | 2016 | 11846 | 0.030 |
Why?
|
| STAT5 Transcription Factor | 1 | 2014 | 86 | 0.030 |
Why?
|
| Transforming Growth Factor beta | 1 | 2017 | 463 | 0.030 |
Why?
|
| Family | 1 | 2017 | 593 | 0.030 |
Why?
|
| STAT1 Transcription Factor | 1 | 2014 | 75 | 0.030 |
Why?
|
| Lung | 1 | 2002 | 1579 | 0.030 |
Why?
|
| DNA-Binding Proteins | 1 | 2022 | 1964 | 0.030 |
Why?
|
| Antigens, CD34 | 1 | 2014 | 100 | 0.030 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 2014 | 72 | 0.030 |
Why?
|
| Antigens, Surface | 1 | 2014 | 114 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2017 | 1525 | 0.020 |
Why?
|
| Radiopharmaceuticals | 1 | 2013 | 166 | 0.020 |
Why?
|
| Pons | 1 | 1993 | 34 | 0.020 |
Why?
|
| Gene Expression | 1 | 2017 | 1508 | 0.020 |
Why?
|
| Demyelinating Diseases | 1 | 1993 | 69 | 0.020 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2014 | 234 | 0.020 |
Why?
|
| Risk Assessment | 2 | 2017 | 3718 | 0.020 |
Why?
|
| Alleles | 1 | 2017 | 1708 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2014 | 771 | 0.020 |
Why?
|
| Cross-Sectional Studies | 2 | 2013 | 3851 | 0.020 |
Why?
|
| HEK293 Cells | 1 | 2014 | 810 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2014 | 831 | 0.020 |
Why?
|
| Alanine Transaminase | 1 | 2012 | 156 | 0.020 |
Why?
|
| Neutrophils | 1 | 1993 | 370 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2014 | 1411 | 0.020 |
Why?
|
| DNA Probes | 1 | 1991 | 120 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2014 | 1522 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2014 | 1571 | 0.020 |
Why?
|
| Immunoprecipitation | 1 | 2011 | 191 | 0.020 |
Why?
|
| Herpesviridae Infections | 2 | 1989 | 140 | 0.020 |
Why?
|
| Autoantibodies | 1 | 1993 | 443 | 0.020 |
Why?
|
| Nucleic Acid Hybridization | 1 | 1991 | 299 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2021 | 4691 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2013 | 1082 | 0.020 |
Why?
|
| Pilot Projects | 2 | 2005 | 1474 | 0.020 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2010 | 62 | 0.020 |
Why?
|
| Signaling Lymphocytic Activation Molecule Associated Protein | 1 | 2009 | 3 | 0.020 |
Why?
|
| Base Sequence | 1 | 1993 | 2783 | 0.020 |
Why?
|
| Family Health | 1 | 2010 | 251 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2011 | 1019 | 0.020 |
Why?
|
| Spleen | 1 | 2010 | 257 | 0.020 |
Why?
|
| Chlorambucil | 1 | 1989 | 5 | 0.020 |
Why?
|
| Chronic Disease | 1 | 1993 | 1240 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 1993 | 3534 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 7 | 1 | 1989 | 77 | 0.020 |
Why?
|
| Diabetes Insipidus, Neurogenic | 1 | 2008 | 5 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 3 | 1 | 1989 | 91 | 0.020 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2017 | 2872 | 0.020 |
Why?
|
| Anemia, Aplastic | 1 | 1988 | 62 | 0.020 |
Why?
|
| Age Factors | 1 | 2014 | 2868 | 0.020 |
Why?
|
| International Cooperation | 1 | 2008 | 162 | 0.020 |
Why?
|
| United Kingdom | 1 | 2008 | 254 | 0.020 |
Why?
|
| Myelodysplastic Syndromes | 1 | 1989 | 133 | 0.020 |
Why?
|
| Mice, Inbred Strains | 1 | 2007 | 275 | 0.020 |
Why?
|
| Canada | 1 | 2008 | 329 | 0.020 |
Why?
|
| Killer Cells, Natural | 1 | 2009 | 344 | 0.020 |
Why?
|
| Immunologic Deficiency Syndromes | 1 | 1989 | 212 | 0.020 |
Why?
|
| Green Fluorescent Proteins | 1 | 2007 | 382 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2010 | 1260 | 0.020 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2009 | 590 | 0.020 |
Why?
|
| Risk | 1 | 2008 | 739 | 0.020 |
Why?
|
| Anti-Bacterial Agents | 1 | 1998 | 2578 | 0.020 |
Why?
|
| Cerebellum | 1 | 2010 | 460 | 0.020 |
Why?
|
| Prevalence | 2 | 2004 | 2705 | 0.010 |
Why?
|
| Chromosome Deletion | 1 | 1989 | 652 | 0.010 |
Why?
|
| CD52 Antigen | 1 | 2005 | 6 | 0.010 |
Why?
|
| Stem Cell Factor | 1 | 2005 | 11 | 0.010 |
Why?
|
| Macrophage Colony-Stimulating Factor | 1 | 2005 | 17 | 0.010 |
Why?
|
| Pregnancy | 1 | 2018 | 7588 | 0.010 |
Why?
|
| Myeloid Progenitor Cells | 1 | 2005 | 15 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2017 | 4696 | 0.010 |
Why?
|
| Leukocyte Count | 1 | 2005 | 249 | 0.010 |
Why?
|
| Ligands | 1 | 2005 | 487 | 0.010 |
Why?
|
| Leiomyosarcoma | 1 | 2003 | 25 | 0.010 |
Why?
|
| Vulva | 1 | 2003 | 15 | 0.010 |
Why?
|
| Neurilemmoma | 1 | 2003 | 42 | 0.010 |
Why?
|
| Infusions, Intravenous | 1 | 2004 | 550 | 0.010 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2003 | 228 | 0.010 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 1989 | 583 | 0.010 |
Why?
|
| Neoplasms, Second Primary | 1 | 2004 | 144 | 0.010 |
Why?
|
| Scalp | 1 | 2003 | 58 | 0.010 |
Why?
|
| Data Collection | 1 | 2004 | 372 | 0.010 |
Why?
|
| Hearing Loss | 1 | 2004 | 211 | 0.010 |
Why?
|
| Aspirin | 1 | 2003 | 217 | 0.010 |
Why?
|
| Regression Analysis | 1 | 2003 | 772 | 0.010 |
Why?
|
| Viral Load | 1 | 2003 | 406 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2004 | 1625 | 0.010 |
Why?
|
| Hepatoblastoma | 1 | 2003 | 196 | 0.010 |
Why?
|
| Societies, Medical | 1 | 2004 | 797 | 0.010 |
Why?
|
| Genes, Viral | 1 | 1998 | 155 | 0.010 |
Why?
|
| Injections, Intravenous | 1 | 1998 | 241 | 0.010 |
Why?
|
| Retroviridae | 1 | 1998 | 182 | 0.010 |
Why?
|
| Drug Resistance, Microbial | 1 | 1998 | 196 | 0.010 |
Why?
|
| Antiviral Agents | 1 | 2003 | 814 | 0.010 |
Why?
|
| Membrane Proteins | 1 | 2005 | 1615 | 0.010 |
Why?
|
| Feasibility Studies | 1 | 1998 | 838 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2003 | 3095 | 0.010 |
Why?
|
| Genetic Vectors | 1 | 1998 | 906 | 0.010 |
Why?
|
| Cell Line | 1 | 1998 | 2591 | 0.010 |
Why?
|
| Mechlorethamine | 1 | 1993 | 7 | 0.010 |
Why?
|
| Procarbazine | 1 | 1993 | 11 | 0.010 |
Why?
|
| Bleomycin | 1 | 1993 | 119 | 0.010 |
Why?
|
| Dacarbazine | 1 | 1993 | 94 | 0.010 |
Why?
|
| Time Factors | 1 | 1988 | 6283 | 0.000 |
Why?
|